Cassava Sciences (SAVA) 10-Q 10 May 24 2024 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 08, 2024
Document Information [Line Items]
Entity Central Index Key	0001069530
Entity Registrant Name	CASSAVA SCIENCES INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2024
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-29959
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	91-1911336
Entity Address, Address Line One	6801 N. Capital of Texas Highway, Building 1; Suite 300
Entity Address, City or Town	Austin
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	78731
City Area Code	512
Local Phone Number	501-2444
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		47,976,166
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, exercisable for shares of Common Stock
Trading Symbol	SAVAW
Security Exchange Name	NASDAQ
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.001 par value
Trading Symbol	SAVA
Security Exchange Name	NASDAQ

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 124,169	$ 121,136
Prepaid expenses and other current assets	9,830	8,497
Total current assets	133,999	129,633
Property and equipment, net	21,604	21,854
Intangible assets, net	115	176
Total assets	155,718	151,663
Current liabilities:
Accounts payable and accrued expenses	9,603	10,573
Accrued development expense	1,797	3,037
Accrued compensation and benefits	228	200
Warrant liabilities	65,368	0
Other current liabilities	125	385
Total current liabilities	77,121	14,195
Commitments and contingencies (Notes 9, 10 and 11)
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding	0	0
Common stock, $0.001 par value; 120,000,000 shares authorized; 43,248,416 and 42,236,919 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	43	42
Additional paid-in capital	434,280	518,195
Retained Earnings (Accumulated Deficit)	(355,726)	(380,769)
Total stockholders' equity	78,597	137,468
Total liabilities and stockholders' equity	$ 155,718	$ 151,663

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2024	Dec. 31, 2023
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	120,000,000	120,000,000
Common stock, shares issued (in shares)	43,248,416	42,236,919
Common stock, shares outstanding (in shares)	43,248,416	42,236,919

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 16,233	$ 22,120
General and administrative	3,701	4,392
Total operating expenses	19,934	26,512
Operating loss	(19,934)	(26,512)
Interest income	1,776	2,051
Other income, net	160	190
Gain from change in fair value of warrant liabilities	43,041	0
Net income (loss)	$ 25,043	$ (24,271)
Shares used in computing net income (loss) per share, basic (in shares)	43,001	41,739
Net income (loss) per share, basic (in dollars per share)	$ 0.58	$ (0.58)
Net income (loss)	$ 25,043	$ (24,271)
Adjustment for change in fair value of warrant liabilities	(43,792)	0
Adjusted numerator, diluted	$ (18,749)	$ (24,271)
Shares used in computing net loss per share, diluted (in shares)	44,102	41,739
Net loss per share, diluted (in dollars per share)	$ (0.43)	$ (0.58)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Share-Based Payment Arrangement, Employee [Member] Common Stock [Member]	Share-Based Payment Arrangement, Employee [Member] Additional Paid-in Capital [Member]	Share-Based Payment Arrangement, Employee [Member] Retained Earnings [Member]	Share-Based Payment Arrangement, Employee [Member]	Share-Based Payment Arrangement, Nonemployee [Member] Common Stock [Member]	Share-Based Payment Arrangement, Nonemployee [Member] Additional Paid-in Capital [Member]	Share-Based Payment Arrangement, Nonemployee [Member] Retained Earnings [Member]	Share-Based Payment Arrangement, Nonemployee [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2022									41,735,557
Balance at Dec. 31, 2022									$ 42	$ 511,049	$ (283,552)	$ 227,539
Stock-based compensation for stock options	$ 0	$ 650	$ 0	$ 650	$ 0	$ 23	$ 0	$ 23
Issuance of common stock pursuant to exercise of stock options (in shares)									13,878			19,017
Issuance of common stock pursuant to exercise of stock options									$ 0	64	0	$ 64
Net income (loss)									$ 0	0	(24,271)	(24,271)
Balance (in shares) at Mar. 31, 2023									41,749,435
Balance at Mar. 31, 2023									$ 42	511,786	(307,823)	204,005
Balance (in shares) at Dec. 31, 2023									42,236,919
Balance at Dec. 31, 2023									$ 42	518,195	(380,769)	$ 137,468
Stock-based compensation for stock options	$ 0	$ 2,312	$ 0	$ 2,312	$ 0	$ 23	$ 0	$ 23
Issuance of common stock pursuant to exercise of stock options (in shares)												0
Net income (loss)									0	0	25,043	$ 25,043
Issuance of warrants									$ 0	(113,363)	0	(113,363)
Issuance of common stock pursuant to exercise of warrants (in shares)									1,011,497
Issuance of common stock pursuant to exercise of warrants									$ 1	22,159	0	22,160
Derecognition of warrant liabilities upon exercise of warrants									$ 0	4,954	0	4,954
Balance (in shares) at Mar. 31, 2024									43,248,416
Balance at Mar. 31, 2024									$ 43	$ 434,280	$ (355,726)	$ 78,597

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net income (loss)	$ 25,043,000	$ (24,271,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	2,335,000	673,000
Gain from change in fair value of warrant liabilities	(43,041,000)	0
Depreciation	250,000	272,000
Amortization of intangible assets	61,000	119,000
Changes in operating assets and liabilities:
Prepaid and other current assets	(1,333,000)	2,679,000
Operating lease right-of-use assets and liabilities	0	(17,000)
Accounts payable and accrued expenses	(970,000)	4,565,000
Accrued development expense	(1,240,000)	2,996,000
Accrued compensation and benefits	28,000	42,000
Other liabilities	(260,000)	(313,000)
Net cash used in operating activities	(19,127,000)	(13,255,000)
Cash flows from investing activities:
Purchases of property and equipment	0	(357,000)
Net cash used in investing activities	0	(357,000)
Cash flows from financing activities:
Proceeds from exercise of common stock warrants, net of exercise costs	22,160,000	0
Proceeds from issuance of common stock upon exercise of stock options	0	64,000
Net cash provided by financing activities	22,160,000	64,000
Net increase (decrease) in cash and cash equivalents	3,033,000	(13,548,000)
Cash and cash equivalents at beginning of period	121,136,000	201,015,000
Cash and cash equivalents at end of period	124,169,000	187,467,000
Non-cash financing activities
Issuance of warrants resulting in recognition of warrant liabilities	113,363,000	0
Derecognition of warrant liabilities upon exercise of warrants	$ (4,954,000)	$ 0

Note 1 - General and Liquidity

Note 1 - General and Liquidity	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Cassava Sciences, Inc. and its wholly-owned subsidiary (collectively referred to as the “Company”) discovers and develops proprietary pharmaceutical product candidates that may The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and pursuant to the instructions to the Quarterly Report on Form 10 10 X. not three March 31, 2024 not may 2024. 10 December 31, 2023 Liquidity The Company has incurred significant net losses and negative cash flows since inception, and as a result has an accumulated deficit of $355.7 million at March 31, 2024 may no 12

Note 2 - Significant Accounting

Note 2 - Significant Accounting Policies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Significant Accounting Policies Use of Estimates The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions. Cash and Cash Equivalents and Concentration of Credit Risk The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three one Fair Value Measurements The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three ● Level 1 ● Level 2 third not 2 ● Level 3 no not 3 If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 March 31, 2024 December 31, 2023 1 March 31, 2024 March 29, 2024, March 31, 2024. The fair value of common stock warrants was determined at distribution on January 3, 2024 not January 3, 2024. 3 Exercise price per warrant $ 33.00 Conversion rate - common shares per warrant 1.50 Closing price of common stock $ 23.72 Volatility 75 % Risk-free interest rate 5.40 % Expected life of option (in years) 0.3 Dividend yield zero Business Segments The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company’s operations are confined to one business segment: the development of novel drugs and diagnostics. Stock-based Compensation  The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four  The Company has granted share-based awards that vest upon achievement of certain performance criteria (“Performance Awards”). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria.  Net Income (Loss) per Share  Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss causes all potentially dilutive securities to be antidilutive. Potential dilutive common shares consist of outstanding common stock options, warrants and performance awards. There is no Three months ended March 31, 2024 2023 Numerator, basic: Net income (loss) $ 25,043 $ (24,271 ) Denominator, basic: Weighted average common shares outstanding 43,001 41,739 Net income (loss) per share, basic $ 0.58 $ (0.58 ) Numerator, diluted: Net income (loss) $ 25,043 $ (24,271 ) Adjustment for change in fair value of warrant liabilities (43,792 ) — Adjusted numerator, diluted $ (18,749 ) $ (24,271 ) Denominator, diluted: Weighted average common shares outstanding 43,001 41,739 Dilutive effect of common stock warrants 1,101 — Weighted average dilutive common shares 44,102 41,739 Net loss per share, diluted $ (0.43 ) $ (0.58 ) Dilutive common stock options excluded from net loss per share, diluted 2,664 2,034 Dilutive performance awards excluded from net loss per share, diluted 7 7 The Company excluded common stock options and performance awards outstanding for the periods ended March 31, 2024 2023 - March 31, 2024 one one Warrant Liabilities The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 480, 480” 815, 815” 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not Fair Value of Financial Instruments Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments may not may Research Contracts, Prepaids and Accruals The Company has entered into various research and development contracts with research institutions and other third not Incentive Bonus Plan In 2020, 2020 718 Stock-based Compensation 10 Leases The Company recognizes assets and liabilities that arise from leases. For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the condensed consolidated balance sheets. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not not Property and equipment Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.2 year. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not Intangible assets Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately 0.1 year at March 31, 2024 March 31, 2024. Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized. Insurance Recoveries We record proceeds from our insurance policies when the loss event has occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $3.0 million and $0.1 million of insurance recoveries recorded during the three March 31, 2024 2023, Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance. The Company accounts for uncertain tax positions in accordance with ASC 740, not Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, 280 2024 2025. In December 2023, No. 2023 09, 740 January 1, 2025.

Note 3 - Prepaid and Other Curr

Note 3 - Prepaid and Other Current Assets	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Prepaid Expenses and Other Current Assets [Text Bock]	Note 3. Prepaid expenses and other current assets at March 31, 2024 December 31, 2023 March 31, December 31, 2024 2023 Prepaid insurance $ 382 $ 759 Contract research organization and other deposits 8,231 6,489 Interest receivable 1,000 962 Other 218 287 Total prepaid expenses and other current assets $ 9,830 $ 8,497 Contract research organization and other deposits represent cash payments made to vendors in excess of expenses incurred.

Note 4 - Real Property and Othe

Note 4 - Real Property and Other Income, Expense	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Real Estate Owned [Text Block]	Note 4. The Company owns a two March 31, 2024 third The Company records the net income from building operations and leases as other income, net, as leasing is not not Three months ended March 31, 2024 2023 Lease revenue $ 403 $ 557 Property operating expenses (243 ) (367 ) Other income, net $ 160 $ 190

Note 5 - Property and Equipment

Note 5 - Property and Equipment	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 5. The components of property and equipment, net, as of March 31, 2024 December 31, 2023 March 31, December 31, 2024 2023 Land $ 3,734 $ 3,734 Buildings 15,980 15,980 Site improvements 494 494 Tenant improvements 3,062 3,062 Furniture and equipment 868 868 Gross property and equipment $ 24,138 $ 24,138 Accumulated depreciation (2,534 ) (2,284 ) Property and equipment, net $ 21,604 $ 21,854 Depreciation expense for property and equipment was $250,000 and $272,000 for the three March 31, 2024 2023

Note 6 - Intangible Assets

Note 6 - Intangible Assets	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	Note 6. The components of intangible assets, net, as of March 31, 2024 December 31, 2023 March 31, December 31, 2024 2023 Lease-in-place agreements $ 1,053 $ 1,053 Leasing commissions and other 293 293 Gross intangible assets $ 1,346 $ 1,346 Accumulated amortization (1,231 ) (1,170 ) Intangible assets, net $ 115 $ 176 Amortization expense for intangible assets was $61,000 and $119,000 for the three March 31, 2024 2023, Amortization expense for finite-lived intangible assets as of March 31, 2024 For the year ending December 31, 2024 $ 111 2025 4 Total amortization $ 115

Note 7 - Stockholders' Equity a

Note 7 - Stockholders' Equity and Stock-based Compensation Expense	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Shareholders' Equity and Share-Based Payments [Text Block]	Note 7. Equity and Stock-Based Compensation Expense Common Stock Warrant Distribution See Notes 2 12 January 3, 2024. At-the-Market Common Stock Offering On May 1, 2023, May 1, 2023 not There were no common stock sales under the ATM during the three March 31, 2024 In March 2020, “2020 May 5, 2020. 2020 April 26, 2023, May 1, 2023. no 2020 Stock Option and Performance Award Activity in 2024 During the three March 31, 2024 Stock Options Performance Awards Outstanding as of December 31, 2023 3,039,029 7,142 Options granted 3,000 — Options exercised — — Options forfeited/canceled — — Outstanding as of March 31, 2024 3,042,029 7,142 The weighted average exercise price per share of options outstanding at March 31, 2024 During the three March 31, 2024 During the three March 31, 2023, not three March 31, 2023. Stock-based Compensation Expense in 2024 During the three March 31, 2024 2023 Three months ended March 31, 2024 2023 Research and development $ 973 $ 389 General and administrative 1,362 284 Total stock-based compensation expense $ 2,335 $ 673 2018 The Company’s Board of Directors (the “Board”) or a designated committee of the Board is responsible for administration of the Company’s 2018 “2018 2018 2018 10 2018 May 5, 2022, 2018  When stock options or Performance Awards are exercised net of the exercise price and taxes, the number of shares of stock issued is reduced by the number of shares equal to the amount of taxes owed by the award recipient and that number of shares are cancelled. The Company then uses its cash to pay tax authorities the amount of statutory taxes owed by and on behalf of the award recipient.

Note 8 - Income Taxes

Note 8 - Income Taxes	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 8. The Company did not three March 31, 2024 2024 three March 31, 2023

Note 9 - Commitments

Note 9 - Commitments	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Leases And Commitments Disclosure [Text Block]	Note 9. Right-of-use Asset and Liability The Company had an operating lease for approximately 6,000 square feet of office space in Austin, Texas with an expiration of April 30, 2024. February 22, 2023 no There was no rent expense for the three March 31, 2024 three March 31, 2023 There was no cash paid for operating lease liabilities during the three March 31, 2024 three March 31, 2023 Other Commitments The Company conducts its product research and development programs through a combination of internal and collaborative programs that include, among others, arrangements with universities, contract research organizations and clinical research sites. The Company has contractual arrangements with these organizations that are cancelable. The Company’s obligations under these contracts are largely based on services performed.

Note 10 - 2020 Cash Incentive B

Note 10 - 2020 Cash Incentive Bonus Plan	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Cash Incentive Bonus Plan [Text Block]	Note 10. 2020 In August 2020, not not 1 2 not March 31, 2024 Plan participants will be paid all earned cash bonuses in the event of a Merger Transaction. As of December 31, 2022, March 16, 2023, not not The Company’s market capitalization for purposes of the Plan is determined based on either ( 1 one 2 The Plan triggers a potential cash bonus each time the Company’s market capitalization increases significantly, up to a maximum $5 no not no If the Company were to exceed a $5 billion market capitalization for no 1 2 may no The Plan is accounted for as a liability award. The fair value of each Valuation Milestone award will be determined once a grant date occurs and will be remeasured each reporting period. Compensation expense associated with the Plan will be recognized over the expected achievement period for each of the 14 Valuation Milestones, when a Performance Condition is considered probable of being met. In October 2020, first 2020, March 2023 During the year ended December 31, 2021, March 2023 no no no No December 31, 2023 2022 three March 31, 2024 No actual cash payments were authorized or made to participants under the Plan through the date of filing of this Form 10

Note 11 - Contingencies

Note 11 - Contingencies	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Contingencies Disclosure [Text Block]	Note 11. The Company is, and from time to time, the Company may may no Government Investigations On November 15, 2021, No No may Securities Class Actions and Shareholder Derivative Actions Between August 27, 2021 October 26, 2021, four On June 30, 2022, four one August 18, 2022 September 14, 2020 July 26, 2022. May 11, 2023, July 3, 2023. February 22, 2024, October 12, 2023. On November 4, 2021, not November 4, 2021 June 20, 2023, two one July 5, 2022, three November 9, 2023, On February 2, 2024, October 12, 2023 August 18, 2022 October 12, 2023. Beginning on March 18, 2024, October 12, 2023 not The Company believes the foregoing claims are without merit and intends to defend against these lawsuits vigorously. The Company is unable to estimate the possible loss or range of loss, if any, associated with these lawsuits. On August 19, 2022, 2020 August 2020. January 6, 2023, March 10, 2023, March 14, 2023. On January 25, 2024, not no

Note 12 - Warrant Dividend Dist

Note 12 - Warrant Dividend Distribution	3 Months Ended
	Mar. 31, 2024
Notes to Financial Statements
Warrant Dividend Distribution [Text Block]	Note 12. On January 3, 2024, December 22, 2023 four 16.9 Each warrant entitled the holder to purchase, at the holder’s sole expense and exclusive election, at an exercise price of $33.00 per warrant, one one On April 15, 2024, May 7, 2024 ( 1/10 January 3, 2024 The warrants were subject to the terms and conditions of the Warrant Agreement (including Form of Warrant), dated January 3, 2024, 8 January 3, 2024. From January 3, 2024 March 31, 2024, March 31, 2024. Subsequent to March 31, 2024 3.15 $104.0 March 31, 2024 Gross proceeds in 2024 After the first Costs of the warrant distribution totaling approximately $512,000 were recorded as general and administrative expenses in the statements of operations upon distribution of the warrants on January 3, 2024. The outstanding warrants are classified as liabilities in accordance with ASC 480 815, January 3, 2024 During the period from common stock warrant distribution on January 3, 2024 March 31, 2024, Number of Common Stock Warrants Common Stock Warrant Liability Distribution of common stock warrants 16,895 $ 113,363 Warrants exercised (674) (4,954) Gain from change in fair value of warrant liabilities — (43,041) Balance as of March 31, 2024 16,221 $ 65,368 See Note 2

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Mar. 31, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	5. Other Information During the quarter ended March 31, 2024 none 16a 1 10b5 1 10b5 1 408.
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2024
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The Company makes estimates and assumptions in preparing its condensed consolidated financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates its estimates on an ongoing basis, including those estimates related to common stock warrant liabilities, clinical trials and manufacturing agreements. Actual results could differ from these estimates and assumptions.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents and Concentration of Credit Risk The Company invests in cash and cash equivalents. The Company considers highly liquid financial instruments with original maturities of three one
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements The Company recognizes financial instruments in accordance with the authoritative guidance on fair value measurements and disclosures for financial assets and liabilities. This guidance defines fair value, establishes a framework for measuring fair value in accordance with GAAP, and expands disclosures about fair value measurements. The guidance also establishes a three ● Level 1 ● Level 2 third not 2 ● Level 3 no not 3 If a financial instrument uses inputs that fall in different levels of the hierarchy, the instrument will be categorized based upon the lowest level of input that is significant to the fair value calculation. The fair value of cash and cash equivalents was based on Level 1 March 31, 2024 December 31, 2023 1 March 31, 2024 March 29, 2024, March 31, 2024. The fair value of common stock warrants was determined at distribution on January 3, 2024 not January 3, 2024. 3 Exercise price per warrant $ 33.00 Conversion rate - common shares per warrant 1.50 Closing price of common stock $ 23.72 Volatility 75 % Risk-free interest rate 5.40 % Expected life of option (in years) 0.3 Dividend yield zero
Segment Reporting, Policy [Policy Text Block]	Business Segments The Company reports segment information based on how it internally evaluates the operating performance of its business units, or segments. The Company’s operations are confined to one business segment: the development of novel drugs and diagnostics.
Compensation Related Costs, Policy [Policy Text Block]	Stock-based Compensation  The Company recognizes non-cash expense for the fair value of all stock options and other share-based awards. The Company uses the Black-Scholes option valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. This model requires the input of subjective assumptions including expected stock price volatility, expected life and estimated forfeitures of each award. These assumptions consist of estimates of future market conditions, which are inherently uncertain, and therefore, are subject to management's judgment. For all options granted, it recognizes the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option, generally four  The Company has granted share-based awards that vest upon achievement of certain performance criteria (“Performance Awards”). The Company multiplies the number of Performance Awards by the fair value of its common stock on the date of grant to calculate the fair value of each award. It estimates an implicit service period for achieving performance criteria for each award. The Company recognizes the resulting fair value as expense over the implicit service period when it concludes that achieving the performance criteria is probable. It periodically reviews and updates as appropriate its estimates of implicit service periods and conclusions on achieving the performance criteria. Performance Awards vest and common stock is issued upon achievement of the performance criteria. 
Earnings Per Share, Policy [Policy Text Block]	Net Income (Loss) per Share  Basic net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net income (loss) per common share is computed by dividing the net income (loss) available to common stockholders by the weighted-average number of common shares outstanding and potentially dilutive securities outstanding during the period using the treasury stock method. Potentially dilutive securities are excluded from the computations of diluted earnings per share if their effect would be antidilutive. A net loss causes all potentially dilutive securities to be antidilutive. Potential dilutive common shares consist of outstanding common stock options, warrants and performance awards. There is no Three months ended March 31, 2024 2023 Numerator, basic: Net income (loss) $ 25,043 $ (24,271 ) Denominator, basic: Weighted average common shares outstanding 43,001 41,739 Net income (loss) per share, basic $ 0.58 $ (0.58 ) Numerator, diluted: Net income (loss) $ 25,043 $ (24,271 ) Adjustment for change in fair value of warrant liabilities (43,792 ) — Adjusted numerator, diluted $ (18,749 ) $ (24,271 ) Denominator, diluted: Weighted average common shares outstanding 43,001 41,739 Dilutive effect of common stock warrants 1,101 — Weighted average dilutive common shares 44,102 41,739 Net loss per share, diluted $ (0.43 ) $ (0.58 ) Dilutive common stock options excluded from net loss per share, diluted 2,664 2,034 Dilutive performance awards excluded from net loss per share, diluted 7 7 The Company excluded common stock options and performance awards outstanding for the periods ended March 31, 2024 2023 - March 31, 2024 one one
Derivatives, Policy [Policy Text Block]	Warrant Liabilities The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and in accordance with the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 480, 480” 815, 815” 480, 480, 815, For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of additional paid-in capital at the time of issuance. For issued or modified warrants that do not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Financial instruments include accounts payable, accrued expenses, accrued development expense and other liabilities. The estimated fair value of certain financial instruments may not may
Research and Development Expense, Policy [Policy Text Block]	Research Contracts, Prepaids and Accruals The Company has entered into various research and development contracts with research institutions and other third not
Share-Based Payment Arrangement [Policy Text Block]	Incentive Bonus Plan In 2020, 2020 718 Stock-based Compensation 10
Lessee, Leases [Policy Text Block]	Leases The Company recognizes assets and liabilities that arise from leases. For operating leases, the Company is required to recognize a right-of-use asset and a lease liability, initially measured at the present value of the lease payments during the lease term, in the condensed consolidated balance sheets. The Company elected the short-term lease recognition exemption for all leases that qualify. This means, for those leases that qualify, the Company does not not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are recorded at cost, net of accumulated depreciation. Depreciation is recorded using the straight-line method over the estimated useful lives of the assets. Owned buildings and related improvements have estimated useful lives of 39 years and approximately 10 years, respectively. Tenant improvements are amortized using the straight-line method over the useful lives of the improvements or the remaining term of the corresponding leases, whichever is shorter. The remaining term of the corresponding leases is approximately 0.2 year. Property and equipment are reviewed for impairment when events or changes in circumstances indicate the carrying amount of an asset may not
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible assets Acquired intangible assets are recorded at fair value at the date of acquisition and primarily consist of lease-in-place agreements and leasing commissions. Intangible assets are amortized over the estimated life of the lease-in-place agreements, which is approximately 0.1 year at March 31, 2024 March 31, 2024. Intangible assets are reviewed for impairment on an annual basis, and when there is reason to believe that their values have been diminished or impaired. If intangible assets are considered to be impaired, an impairment loss is recognized.
Commitments and Contingencies, Policy [Policy Text Block]	Insurance Recoveries We record proceeds from our insurance policies when the loss event has occurred, and proceeds are estimable and probable of being recovered. Insurance recoveries and proceeds received are recorded as a reduction to general and administrative expense. There was approximately $3.0 million and $0.1 million of insurance recoveries recorded during the three March 31, 2024 2023,
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax balances are adjusted to reflect tax rates based on currently enacted tax laws, which will be in effect in the years in which the temporary differences are expected to reverse. The Company has accumulated significant deferred tax assets that reflect the tax effects of net operating loss and tax credit carryovers and temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Realization of certain deferred tax assets is dependent upon future earnings. The Company is uncertain about the timing and amount of any future earnings. Accordingly, the Company offsets these deferred tax assets with a valuation allowance. The Company accounts for uncertain tax positions in accordance with ASC 740, not
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements In November 2023, No. 2023 07, 280 2024 2025. In December 2023, No. 2023 09, 740 January 1, 2025.

Note 2 - Significant Accounti_2

Note 2 - Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]	Exercise price per warrant $ 33.00 Conversion rate - common shares per warrant 1.50 Closing price of common stock $ 23.72 Volatility 75 % Risk-free interest rate 5.40 % Expected life of option (in years) 0.3 Dividend yield zero
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three months ended March 31, 2024 2023 Numerator, basic: Net income (loss) $ 25,043 $ (24,271 ) Denominator, basic: Weighted average common shares outstanding 43,001 41,739 Net income (loss) per share, basic $ 0.58 $ (0.58 ) Numerator, diluted: Net income (loss) $ 25,043 $ (24,271 ) Adjustment for change in fair value of warrant liabilities (43,792 ) — Adjusted numerator, diluted $ (18,749 ) $ (24,271 ) Denominator, diluted: Weighted average common shares outstanding 43,001 41,739 Dilutive effect of common stock warrants 1,101 — Weighted average dilutive common shares 44,102 41,739 Net loss per share, diluted $ (0.43 ) $ (0.58 ) Dilutive common stock options excluded from net loss per share, diluted 2,664 2,034 Dilutive performance awards excluded from net loss per share, diluted 7 7

Note 3 - Prepaid and Other Cu_2

Note 3 - Prepaid and Other Current Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	March 31, December 31, 2024 2023 Prepaid insurance $ 382 $ 759 Contract research organization and other deposits 8,231 6,489 Interest receivable 1,000 962 Other 218 287 Total prepaid expenses and other current assets $ 9,830 $ 8,497

Note 4 - Real Property and Ot_2

Note 4 - Real Property and Other Income, Expense (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	Three months ended March 31, 2024 2023 Lease revenue $ 403 $ 557 Property operating expenses (243 ) (367 ) Other income, net $ 160 $ 190

Note 5 - Property and Equipme_2

Note 5 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, 2024 2023 Land $ 3,734 $ 3,734 Buildings 15,980 15,980 Site improvements 494 494 Tenant improvements 3,062 3,062 Furniture and equipment 868 868 Gross property and equipment $ 24,138 $ 24,138 Accumulated depreciation (2,534 ) (2,284 ) Property and equipment, net $ 21,604 $ 21,854

Note 6 - Intangible Assets (Tab

Note 6 - Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	March 31, December 31, 2024 2023 Lease-in-place agreements $ 1,053 $ 1,053 Leasing commissions and other 293 293 Gross intangible assets $ 1,346 $ 1,346 Accumulated amortization (1,231 ) (1,170 ) Intangible assets, net $ 115 $ 176
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	For the year ending December 31, 2024 $ 111 2025 4 Total amortization $ 115

Note 7 - Stockholders' Equity_2

Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Share-Based Payment Arrangement, Activity [Table Text Block]	Stock Options Performance Awards Outstanding as of December 31, 2023 3,039,029 7,142 Options granted 3,000 — Options exercised — — Options forfeited/canceled — — Outstanding as of March 31, 2024 3,042,029 7,142
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three months ended March 31, 2024 2023 Research and development $ 973 $ 389 General and administrative 1,362 284 Total stock-based compensation expense $ 2,335 $ 673

Note 12 - Warrant Dividend Di_2

Note 12 - Warrant Dividend Distribution (Tables)	3 Months Ended
	Mar. 31, 2024
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	Number of Common Stock Warrants Common Stock Warrant Liability Distribution of common stock warrants 16,895 $ 113,363 Warrants exercised (674) (4,954) Gain from change in fair value of warrant liabilities — (43,041) Balance as of March 31, 2024 16,221 $ 65,368

Note 1 - General and Liquidity

Note 1 - General and Liquidity (Details Textual) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Retained Earnings (Accumulated Deficit)	$ (355,726)	$ (380,769)

Note 2 - Significant Accounti_3

Note 2 - Significant Accounting Policies (Details Textual) $ in Millions	3 Months Ended
	Mar. 31, 2024 USD ($) shares	Mar. 31, 2023 USD ($)	Jan. 03, 2024 shares
Number of Operating Segments	1
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 months 12 days
Proceeds from Insurance Settlement, Operating Activities | $	$ 3	$ 0.1
Leases, Acquired-in-Place [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 month 6 days
Lease Commissions and Other [Member]
Finite-Lived Intangible Asset, Useful Life (Year)	1 year
Building [Member]
Property, Plant and Equipment, Useful Life (Year)	39 years
Building Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	10 years
Warrants to Purchase Common Stock [Member]
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares) | shares	1.5		1.5
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period (Year)	4 years

Note 2 - Significant Accounti_4

Note 2 - Significant Accounting Policies - Quantitive Information of Warrants (Details) - Warrants to Purchase Common Stock [Member]	Mar. 31, 2024
Measurement Input, Exercise Price [Member]
Warrant measurement	33
Measurement Input, Conversion Price [Member]
Warrant measurement	1.5
Measurement Input, Share Price [Member]
Warrant measurement	23.72
Measurement Input, Price Volatility [Member]
Warrant measurement	0.75
Measurement Input, Risk Free Interest Rate [Member]
Warrant measurement	0.054
Measurement Input, Expected Term [Member]
Warrant measurement	0.3
Measurement Input, Expected Dividend Rate [Member]
Warrant measurement	0

Note 2 - Significant Accounti_5

Note 2 - Significant Accounting Policies - Calculation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Net income (loss)	$ 25,043	$ (24,271)
Shares used in computing net income (loss) per share, basic (in shares)	43,001	41,739
Net income (loss) per share, basic (in dollars per share)	$ 0.58	$ (0.58)
Adjustment for change in fair value of warrant liabilities	$ (43,792)	$ 0
Adjusted numerator, diluted	$ (18,749)	$ (24,271)
Dilutive effect of common stock warrants (in shares)	1,101	0
Weighted average dilutive common shares (in shares)	44,102	41,739
Net loss per share, diluted (in dollars per share)	$ (0.43)	$ (0.58)
Share-Based Payment Arrangement, Option [Member]
Dilutive awards excluded from net loss per share, diluted (in shares)	2,664	2,034
Warrant [Member]
Dilutive awards excluded from net loss per share, diluted (in shares)	7	7

Note 3 - Prepaid Expenses and O

Note 3 - Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Prepaid insurance	$ 382	$ 759
Contract research organization and other deposits	8,231	6,489
Interest receivable	1,000	962
Other	218	287
Total prepaid expenses and other current assets	$ 9,830	$ 8,497

Note 4 - Real Property and Ot_3

Note 4 - Real Property and Other Income, Expense (Details Textual) - Office Building [Member] - TEXAS - ft²	Mar. 31, 2024	Aug. 04, 2021
Net Rentable Area (Square Foot)		90,000
Percentage of Occupancy	25%

Note 4 - Real Property and Ot_4

Note 4 - Real Property and Other Income, Expense - Components of Other Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Lease revenue	$ 403	$ 557
Property operating expenses	(243)	(367)
Other income, net	$ 160	$ 190

Note 5 - Property and Equipme_3

Note 5 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Depreciation	$ 250,000	$ 272,000

Note 5 - Property and Equipme_4

Note 5 - Property and Equipment - Components of Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross property and equipment	$ 24,138	$ 24,138
Accumulated depreciation	(2,534)	(2,284)
Property and equipment, net	21,604	21,854
Land [Member]
Gross property and equipment	3,734	3,734
Building [Member]
Gross property and equipment	15,980	15,980
Building Improvements [Member]
Gross property and equipment	494	494
Leasehold Improvements [Member]
Gross property and equipment	3,062	3,062
Furniture and Fixtures [Member]
Gross property and equipment	$ 868	$ 868

Note 6 - Intangible Assets (Det

Note 6 - Intangible Assets (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Amortization of Intangible Assets	$ 61,000	$ 119,000

Note 6 - Intangible Assets - Co

Note 6 - Intangible Assets - Components of Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Gross intangible assets	$ 1,346	$ 1,346
Accumulated amortization	(1,231)	(1,170)
Total amortization	115	176
Leases, Acquired-in-Place [Member]
Gross intangible assets	1,053	1,053
Leasing Commissions and Other [Member]
Gross intangible assets	$ 293	$ 293

Note 6 - Intangible Assets - Am

Note 6 - Intangible Assets - Amortization Expense for Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
2024	$ 111
2025	4
Total amortization	$ 115	$ 176

Note 7 - Stockholders' Equity_3

Note 7 - Stockholders' Equity and Stock-based Compensation Expense (Details Textual) - USD ($)		3 Months Ended
	May 05, 2022	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	May 01, 2023	Mar. 31, 2020
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price (in dollars per share)		$ 15.14
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)		2 years 7 months 6 days
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount		$ 21,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)		0	19,017
Proceeds from Stock Options Exercised		$ 0	$ 64,000
Common Stock, Par or Stated Value Per Share (in dollars per share)		$ 0.001		$ 0.001
The 2018 Equity Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period (Year)	10 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized (in shares)	5,000,000
Common Stock, Par or Stated Value Per Share (in dollars per share)	$ 0.001
Performance Shares [Member]
Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount		$ 100,000
Stock Options Net Settled in Satisfaction of the Exercise Price [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period (in shares)			5,139
Proceeds from Stock Options Exercised			$ 0
At-the-market Common Stock Offering [Member]
Equity Offering, Maximum Amount					$ 200,000,000	$ 100,000,000
Equity Offering, Percentage of Commission					3%
Stock Issued During Period, Shares, New Issues (in shares)		0

Note 7 - Stockholders' Equity_4

Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock Option and Performance Award Activity (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Outstanding, options (in shares)	3,039,029
Options granted (in shares)	3,000
Options exercised (in shares)	0	(19,017)
Options forfeited/canceled (in shares)	0
Outstanding, options (in shares)	3,042,029
Performance Shares [Member]
Outstanding, performance awards (in shares)	7,142
Performance awards granted (in shares)	0
Performance awards exercised (in shares)	0
Performance awards forfeited/canceled (in shares)	0
Outstanding, performance awards (in shares)	7,142

Note 7 - Stockholders' Equity_5

Note 7 - Stockholders' Equity and Stock-based Compensation Expense - Stock-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Total stock-based compensation expense	$ 2,335	$ 673
Research and Development Expense [Member]
Total stock-based compensation expense	973	389
General and Administrative Expense [Member]
Total stock-based compensation expense	$ 1,362	$ 284

Note 8 - Income Taxes (Details

Note 8 - Income Taxes (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Income Tax Expense (Benefit)	$ 0	$ 0

Note 9 - Commitments (Details T

Note 9 - Commitments (Details Textual)	3 Months Ended
	Mar. 31, 2024 USD ($)	Mar. 31, 2023 USD ($)	Feb. 22, 2023 ft²
Operating Lease, Cost	$ 0	$ 24,000
Operating Lease, Payments	$ 0	$ 24,000
Lease for Office Space in Austin, Texas [Member]
Area of Real Estate Property (Square Foot) | ft²			6,000

Note 10 - 2020 Cash Incentive_2

Note 10 - 2020 Cash Incentive Bonus Plan (Details Textual) - Cash Incentive Bonus Plan [Member] $ in Thousands		3 Months Ended		12 Months Ended
	Mar. 16, 2023 USD ($)	Mar. 31, 2024 USD ($)	Mar. 16, 2023 USD ($)	Dec. 31, 2021 USD ($)	Oct. 31, 2020 USD ($)
Cash Bonus Incentive, Incremental Amounts	14		14	11
Performance Plan, Minimum Number of Days Valuation Milestone Must be Achieved and Maintained (Day)	20 days		20 days
Percentage Valuation Milestone Cash Bonus Award Subject to Approval and Adjustment	67%		67%
Cash Incentive Bonus Award					$ 6,500
Share-Based Payment Arrangement, Expense, after Tax				$ 0
Payments for Cash Incentive Bonus		$ 0
Minimum [Member]
Performance Plan, Valuation Milestone Amount	$ 200,000		$ 200,000	74,900
Cash Incentive Bonus Award, Exceeds Maximum	111,400		111,400
Maximum [Member]
Performance Plan, Valuation Milestone Amount	5,000,000		5,000,000	$ 202,300
Cash Incentive Bonus Award, Exceeds Maximum	$ 289,700		$ 289,700

Note 11 - Contingencies (Detail

Note 11 - Contingencies (Details Textual)				2 Months Ended	20 Months Ended
	Mar. 18, 2024	Jul. 05, 2022	Jun. 30, 2022	Oct. 26, 2021	Jun. 20, 2023	Jun. 20, 2023
Violations of Federal Securities Laws [Member]
Loss Contingency, New Claims Filed, Number			1	4
Shareholder Derivative Actions, Texas Court [Member]
Loss Contingency, New Claims Filed, Number					4	2
Shareholder Derivative Actions, Texas State Court Member
Loss Contingency, New Claims Filed, Number						1
Shareholder Derivative Actions, Delaware Court [Member]
Loss Contingency, New Claims Filed, Number						1
Shareholder Derivative Actions [Member]
Loss Contingency, New Claims Filed, Number	2	3

Note 12 - Warrant Dividend Di_3

Note 12 - Warrant Dividend Distribution (Details Textual) - USD ($)			1 Months Ended	3 Months Ended
	Jan. 03, 2024	Dec. 22, 2023	May 02, 2024	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023	May 07, 2024
Proceeds from Warrant Exercises				$ 22,160,000		$ 0
Warrants to Purchase Common Stock [Member]
Class Of Warrant Or Right Issued During Period (in shares)	16,900,000	4		16,895,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)		10		5,700,000	5,700,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)	$ 33			$ 22	$ 22
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right (in shares)	1.5			1.5	1.5
Class of Warrant or Right, Exercised During Period (in shares)				(674,000)	674,000
Proceeds from Warrant Exercises					$ 22,300,000
Stock Issued During Period, Shares, Warrant Exercises (in shares)					1
Gross Proceeds From Issuance of Warrants				$ 126,300,000
Proceeds from Issuance of Warrants				123,500,000
Proceeds From Warrants Exercised That Obligated to Pay Commission					$ 20,000,000
Commission Percentage of Gross Proceeds					2.50%
Payments of Warrant Exercise Costs				$ 2,800,000
Payments of Stock Issuance Costs	$ 512,000
Warrants to Purchase Common Stock [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, Warrant Exercises (in shares)			4.7
Warrants to Purchase Common Stock [Member] | Forecast [Member]
Redemption Percentage of Warrants							0.10%
Warrant Redemption Price (in dollars per share)							$ 0.01

Note 12 - Warrant Dividend Di_4

Note 12 - Warrant Dividend Distribution - Changes in Warrants Outstanding and Warrant Liability (Details) - USD ($)			3 Months Ended
	Jan. 03, 2024	Dec. 22, 2023	Mar. 31, 2024	Mar. 31, 2024	Mar. 31, 2023
Distribution of common stock warrants, liability			$ 113,363,000		$ 0
gain from change in fair value of warrant liabilities, liability			$ 43,041,000		$ 0
Warrants to Purchase Common Stock [Member]
Class Of Warrant Or Right Issued During Period (in shares)	16,900,000	4	16,895,000
Distribution of common stock warrants, liability			$ 113,363
Class of Warrant or Right, Exercised During Period (in shares)			(674,000)	674,000
Warrants exercised, liability			$ (4,954)
gain from change in fair value of warrant liabilities, liability			$ (43,041)
Balance, shares (in shares)			16,221,000	16,221,000
Balance, liability			$ 65,368	$ 65,368